Introduction Management of central nervous system (CNS) metastases in patients with driver-
mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and …

Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However,
tumor suppressors cannot be directly targeted because of their loss of function. To uncover …

With the development of genome sequencing, the role of molecular targeted therapy in
cancer is becoming increasingly important. However, genetic testing remains expensive …

Nanomedicines for cancer treatment have been studied extensively over the last few
decades. Yet, only five anticancer nanomedicines have received approvals from the United …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Introduction: We retrospectively assessed prognostic value of circulating cell-free DNA
(cfDNA) using data from the phase III ALEX study in treatment-naïve, advanced ALK+ …

Targeted therapy has stepped into the perioperative treatment arena and launched a radical
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …

The MET gene, known as MET proto-oncogene receptor tyrosine kinase, was first identified
to induce tumor cell migration, invasion, and proliferation/survival through canonical RAS …

Non‑small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality
rate that is a threat to human health. With the development of molecular targeted research …

Considering the increasing number of identified driver oncogene alterations, additional
genetic tests are required to determine the treatment for advanced non‐small‐cell lung …